InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2020-11-13 | Greg Gianforte | house | Purchase | $15,001 - $50,000 |
| 2016-09-12 | K. Michael Conaway(D-TX11) | house | Sale | $1,001 - $15,000 |
| 2016-05-11 | K. Michael Conaway(D-TX11) | house | Sale | $1,001 - $15,000 |
| 2015-09-11 | Alan S. Lowenthal | house | Sale | $15,001 - $50,000 |
| 2015-07-27 | Alan S. Lowenthal | house | Sale | $15,001 - $50,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net revenues | $17.26B+4.3% | $16.54B+4.4% | $15.85B+6.2% | $14.93B-6.0% | $15.88B |
| Cost of sales | $8.32B-1.9% | $8.48B+3.4% | $8.20B+3.1% | $7.95B-4.0% | $8.28B |
| Gross profit | $8.94B+10.8% | $8.06B+5.5% | $7.64B+9.6% | $6.97B-8.2% | $7.59B |
| Research and development expenses, net | $1.01B+1.5% | $998.0M+4.7% | $953.0M+13.7% | $838.0M-13.3% | $967.0M |
| Selling and marketing expenses | $2.69B+5.7% | $2.54B+8.8% | $2.34B+3.1% | $2.27B-6.8% | $2.43B |
| General and administrative expenses | $1.29B+10.9% | $1.16B-0.1% | $1.16B-1.5% | $1.18B+7.4% | $1.10B |
| Intangible assets impairments | $259.0M+3.2% | $251.0M-28.3% | $350.0M-1.4% | $355.0M-16.3% | $424.0M |
| Goodwill impairment | $0-100.0% | $1.28B+82.9% | $700.0M-65.8% | $2.04B | $0 |
| Other asset impairments, restructuring and other items | $1.05B-24.4% | $1.39B+93.3% | $718.0M+40.2% | $512.0M+50.1% | $341.0M |
| Legal settlements and loss contingencies | $467.0M-38.6% | $761.0M-27.0% | $1.04B-49.9% | $2.08B+190.4% | $717.0M |
| Other loss (income) | $18.0M+228.6% | -$14.0M+71.4% | -$49.0M+54.2% | -$107.0M | — |
| Operating income (loss) | $2.16B+811.9% | -$303.0M-170.0% | $433.0M+119.7% | -$2.20B | — |
| Financial expenses – net | $934.0M-4.8% | $981.0M-7.2% | $1.06B+9.4% | $966.0M-8.7% | $1.06B |
| Income (loss) before income taxes | $1.22B+195.2% | -$1.28B-105.8% | -$624.0M+80.3% | -$3.16B-580.7% | $658.0M |
| Income taxes (benefit) | -$180.0M-126.6% | $676.0M+9757.1% | -$7.0M+98.9% | -$643.0M-404.7% | $211.0M |
| Share in (profits) losses of associated companies – net | -$15.0M-1400.0% | -$1.0M+50.0% | -$2.0M+90.5% | -$21.0M-133.3% | -$9.0M |
| Net income (loss) | $1.42B+172.4% | -$1.96B-218.5% | -$615.0M+75.4% | -$2.50B-648.0% | $456.0M |
| Net income (loss) attributable to redeemable and non-redeemable non-controlling interests | $7.0M+102.2% | -$320.0M-471.4% | -$56.0M | — | — |
| Net income (loss) attributable to Teva | $1.41B+186.0% | -$1.64B-193.2% | -$559.0M+77.1% | -$2.45B-686.6% | $417.0M |
| Basic | $1.15B+1.2% | $1.13B+1.1% | $1.12B+0.8% | $1.11B+0.7% | $1.10B |
| Diluted | $1.16B+2.8% | $1.13B+1.1% | $1.12B+0.8% | $1.11B+0.3% | $1.11B |
| Basic | $1.15B+1.2% | $1.13B+1.1% | $1.12B+0.8% | $1.11B+0.7% | $1.10B |
| Diluted | $1.16B+2.8% | $1.13B+1.1% | $1.12B+0.8% | $1.11B+0.3% | $1.11B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Teva Pharmaceutical Industries Positioned for Re-Rating on Growth Drivers, UBS Says
A Look At Teva (NYSE:TEVA) Valuation After Robust First Quarter 2026 Earnings Reaction
TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up
Analysis of the 2026 Oral Solid Dosage Contract Manufacturing Market - Scalable Pharma Solutions & Generic Demand Drive $59.05 Billion Forecast for 2030